Patents Assigned to Synthelabo
  • Patent number: 6844335
    Abstract: A pyrimidone derivative represented by formula (I) or a salt thereof: Wherein: R1 represents a hydrogen atom or a C1-6 alkyl group which may be substituted by a C6,10 aryl group; R2 represents a C1-10 alkyl group which may be substituted, a C2-6 alkenyl group which may be substituted, a C3-6 alkynyl group which may be substituted, a C3-6 cycloalkyl group which may be substituted, or a C6-10 ARYL group which may be substituted; or R1 and R2 form together a C2-6 alkylene group which may be substituted; or R1 and R2 form together a chain of formula —(CH2)2—X—(CH2)2— or —(CH2)2—X—(CH2)3— where X represents a oxygen atom, a sulfur atom, or a nitrogen atom which may be substituted; R3 represents a 2, 3 or 4-pyridyl group optionally substituted by a C1-4 alkyl group, C1-4 alkoxy group or halogen atom; and R4 represents a C1-10 alkyl group optionally substituted by a hydroxyl group, amino, C1-6 monoalkylamino group, C2-12 dialkylamino group or C6,10 aryl group which may be substituted.
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: January 18, 2005
    Assignees: Sanofi-Synthelabo, Mitsubishi Pharma Corporation
    Inventors: Antonio Almario Garcia, Ryoichi Ando, Keiichi Arimoto, Fumiaki Uehara, Adrien Tak Li, Aya Shoda, Jonathan Reid Frost, Kazutoshi Watanabe
  • Patent number: 6844329
    Abstract: The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing avidin or streptavidin which makes it possible to neutralize these polysaccharides.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: January 18, 2005
    Assignee: Sanofi-Synthelabo
    Inventors: Philippe Duchaussoy, Jean-Marc Herbert, Maurice Petitou, Pierre Savi
  • Patent number: 6844337
    Abstract: Compounds corresponding to general formula (I) in which R1, R2, R3, R4 and R5 each represent, independently of one another, a hydrogen or halogen atom or a nitro, amino, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, (C1-C6)alkyl, (C1-C6)alkoxy or phenyl group, it also being possible for two of these substituents in adjacent positions together to represent a methylenedioxy group, and R6 represents a hydrogen atom or a (C1-C6)alkyl group. Application in therapeutics.
    Type: Grant
    Filed: May 29, 2001
    Date of Patent: January 18, 2005
    Assignee: Sanofi-Synthelabo
    Inventors: Frédéric Galli, Odile Leclerc, Alistair Lochead
  • Patent number: 6835730
    Abstract: Compounds of the general formula (I) in which R1, R2, R3 and R4 each represent a hydrogen or halogen atom or a nitro, amino, trifluoromethyl, cyano, hydroxyl, alkyl or alkoxy group, X represents either a nitrogen atom, in which case Z represents a group of the formula C—R5 or a nitrogen atom, or a group of the formula C—R6, in which case Z represents a nitrogen atom, R5 and R6 each represent a hydrogen or halogen atom or a trifluoromethyl, cyano, hydroxyl, (C1-C6)alkyl or (C1-C6)alkoxy group, and R7 represents a hydrogen atom or a (C1-C6)alkyl group. Use in therapy.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: December 28, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Frédéric Galli, Samir Jegham, Odile Leclerc, Alistair Lochead, Alain Nedelec
  • Patent number: 6828448
    Abstract: The invention relates to 2-butyl-5-(methanesulfonamido)benzofuran, its preparation and its use. This compound is a synthesis intermediate, in particular for the preparation of dronedarone.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: December 7, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Noël Fino, Corinne Leroy
  • Patent number: 6806282
    Abstract: The present invention relates to novel branched substituted amino derivatives of 3-amino-1-phenyl-1H-[1,2,4]triazole, processes for their preparation and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: October 19, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Michel Geslin, Danielle Gully, Jean-Pierre Maffrand, Pierre Roger
  • Patent number: 6800761
    Abstract: The invention relates to a novel crystalline form of irbesartan, to pharmaceutical compositions containing it, to processes for preparing it, and to a method for treating cardiovascular diseases utilizing it.
    Type: Grant
    Filed: March 12, 2001
    Date of Patent: October 5, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Bruno Franc, Christian Hoff, San Kiang, Mark D. Lindrud, Olivier Monnier, Chenkou Wei
  • Patent number: 6794382
    Abstract: The invention relates to benzimidazole derivatives of general formula in which X represents a nitrogen atom or a carbon atom; and when X represents a nitrogen atom: R3 represents a hydrogen atom or a C1-C4 alkyl group, or does not exist, to give the compounds of formula (I) comprising a secondary or tertiary amine; R4 represents a hydrogen atom or a C1-C6 alkyl, C3-C7 cycloalkyl, optionally substituted C3-C7 heterocycloalkyl, —(CH2)p-heteroaryl, heteroaryl-carbonyl, phenylcarbonyl, (C1-C6)alkylcarbonyl, —(CH2)pCOOR, optionally substituted phenylsulphonyl or optionally substituted —(CH2)p-phenyl group, and, when X represents a carbon atom: R3 represents a hydrogen atom or a group —NR5R6, —N(R5)3+, —NHCOR7, —CONHR5, —COR7, —NHCONH2, —OH or —CH2OH, R4 represents a hydrogen atom or an optionally substituted —(CH2)p-phenyl, —(CH2)p-heteroaryl or —(CH2)tNR7R8 group.
    Type: Grant
    Filed: January 30, 2003
    Date of Patent: September 21, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Francis Barth, Daniel Bichon, Frank Bolkenius, Viviane Van Dorsselaer
  • Patent number: 6767533
    Abstract: A composition containing a peripheral benzodiazepine receptor ligand for topical use in the treatment of cutaneous stress.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: July 27, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Pierre Casellas, Jean-Marie Derocq
  • Patent number: 6761879
    Abstract: The invention relates to a titanium-derived compounds, and to processes for preparing the same.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: July 13, 2004
    Assignee: Sanofi-Synthelabo
    Inventor: Claudine Finidori
  • Patent number: 6730695
    Abstract: The invention relates to compounds of formula: as well as the possible salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, which have affinity for and selectivity towards the V1b receptors or towards both the V1b and V1a receptors of arginine-vasopressin. The invention also relates to the process for preparing them, to the intermediate compounds of formula (II) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for the preparation of medicinal products.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: May 4, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Richard Roux, Claudine Serradeil-Le Gal, Bernard Tonnerre, Jean Wagnon
  • Patent number: 6713053
    Abstract: The use of interleukin 7 or T cells pre-incubated in the presence of IL-7 for preparing a drug or pharmaceutical composition for treating an auto-immune disease, particularly an auto-immune disease induced by a defect in CD4+ T cell immunoregulation, is disclosed.
    Type: Grant
    Filed: August 18, 1998
    Date of Patent: March 30, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Jean Francois Bach, Jean Marc Gombert, Andre Herbelin, Michel Morre
  • Patent number: 6710042
    Abstract: Compounds of formula (I) are useful as human NK3 receptor antagonists.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: March 23, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Daniel Bichon, Xavier Edmonds-Alt, Patrick Gueule, Vincenzo Proietto, Didier Van Broeck
  • Patent number: 6693118
    Abstract: The invention relates to the use of a compound of formula (I): for the preparation of pharmaceutical compositions for increasing the circulating, cellular and extracellular levels of TGF-&bgr;1.
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: February 17, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Françoise Bono-Combie, Jacqueline Fournier, Jean Marc Herbert, Isabelle Lamarche, Umberto Guzzi
  • Patent number: 6689797
    Abstract: The present invention relates to compounds of formula (I): in which R1 represents a hydrogen or halogen atom, or a group CF3; R2 and R3 represent, independently, a hydrogen atom or a methyl group; n and n′ each represent, independently, 0 or 1; * represents the positions of attachment; A represents N or CH; X represents a sulfur or oxygen atom; R4 and R5 represent, independently, a hydrogen atom or a (C1-C6) alkyl group; and also their salts or solvates, to a method for the preparation thereof and to the pharmaceutical compositions containing them.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: February 10, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Marco Baroni, Bernard Bourrie, Rosanna Cardamone, Pierre Casellas
  • Patent number: 6686182
    Abstract: The invention relates to lower-alkyl esters of 3-(3,4-dihalophenyl)-2,6-dioxopiperidine-3-propionic acid derivatives, and to processes for preparing the same.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: February 3, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Bertrand Castro, Jean-Robert Dormoy, Alain Rabion
  • Patent number: 6680329
    Abstract: Compounds of formula [I] in which: W may represent a —(CH2)2—, —(CH2)3—, —CH2—C≡C— or —CH2—CH═CH— group, R2 may in particular represent a piperidyl group, an optionally substituted 1,2,3,6-tetrahydropyridyl group, a hexahydro-1H-azepinyl group, an optionally substituted piperazinyl group or a morpholinyl group, R3 may in particular represent a group —COR1, A may in particular represent an optionally substituted phenyl group, a heterocycle or a cyclopentyl group, and B may in particular represent a pyridyl group, an aminopyrazinyl group, an aminopyridazinyl group, a pyrimidinyl group optionally substituted with an amino group, piperidyl group or an aminopyridyl group optionally substituted on the pyridine with a (C1-C4)alkyl or (C1-C4)alkoxy group, the amino group possibly also being substituted with a (C1-C4)alkyl group, their preparation and their therapeutic application.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: January 20, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Jean-Michel Altenburger, Gérard Cremer, Gilbert Lassalle, Mostafa Matrougui
  • Patent number: 6673790
    Abstract: The present invention relates to novel indolin-2-one derivatives of formula: to the preparation and to the pharmaceutical compositions comprising them. These compounds have an affinity for oxytocin receptors.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: January 6, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Loïc Foulon, Georges Garcia, Claudine Serradeil-Le Gal, Gérard Valette
  • Patent number: 6670486
    Abstract: The invention relates to the racemisation process of the optically active [2-(2-thienyl)ethylamino](2-halogenophenyl)acetamides of general formula (VII) by using basic compounds. The resulting racemic compounds of general formula (VII) can thus be recycled into synthesis of the therapeutically useful compounds of general formula (VI).
    Type: Grant
    Filed: June 18, 2001
    Date of Patent: December 30, 2003
    Assignee: Sanofi-Synthelabo
    Inventors: Mária Bakonyl, Tiborné Bai, Zsolt Dombrády, Katalin Gáspár, Attila Supic
  • Patent number: 6670338
    Abstract: Pentasaccharides in acidic form and their pharmaceutically acceptable salts, the anionic form thereof having the formula: wherein: R represents hydrogen or an —SO3−, (C1-C3)alkyl or (C2-C3)acyl group; T represents hydrogen or an ethyl group; and n represents 1 or 2 for use in the treatment of pathologies associated with a clotting dysfunction.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: December 30, 2003
    Assignee: Sanofi-Synthelabo
    Inventor: Maurice Petitou